Početna › Pločastostanični karcinom glave i vrata › Utah
Kliničke studije za Pločastostanični karcinom glave i vrata u državi Utah
21 studija za Pločastostanični karcinom glave i vrata traži sudionike na lokacijama u državi Utah.
Gradovi u državi Utah
Službeni tekst studije (engleski)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Farmington Health Center, Farmington
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06992427A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06465069A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07085091BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Huntsman Cancer Institute/University of Utah, Salt Lake City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Huntsman Cancer Institute, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Utah Huntsman Cancer Institute, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06385080Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT05267626A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT05059444Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 13. kol 2026. · NCT05985655A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. srp 2026. · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 7. srp 2026. · NCT05768139Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. lip 2026. · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START Mountain Region, LLC, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. lip 2026. · NCT07503808Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. lip 2026. · NCT07517198Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
- Huntsman Cancer Institute/University of Utah, Salt Lake City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 27. velj 2026. · NCT07044635Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. velj 2026. · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 do 80 godina · Oba spola · Ažurirano 11. pro 2025. · NCT03556228Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.